Angioimmunoblastic T-Cell Lymphoma

Updated: Apr 24, 2020

Author: Amira M Elbendary, MD, MBBCh, MSc; Chief Editor: Dirk M Elston, MD

Overview

Background

In 1974, Frizzera et al[1] described angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). In some classifications, similar atypical lymphoproliferative disorders were later grouped as lymphogranulomatosis X or immunoblastic lymphadenopathy. The disorder is now classified as angioimmunoblastic T-cell lymphoma (AITL). Both terms are in common use.

AITL is a type of peripheral T-cell lymphoma (PTCL) that is clinically characterized by high fever and generalized lymphadenopathy. Approximately 40-50% of patients also have cutaneous involvement. As the disorder progresses, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia may develop. In one series, other symptoms included weight loss (58%), hepatomegaly (60%), polyclonal hyperglobulinemia (65%), and generalized adenopathy (87%). Patients are usually aged 40-90 years.

AITL may represent a spectrum of disease ranging from a hyperplastic but still benign immune reaction to frank malignant lymphoma. Because clonal expansion of T cells has been demonstrated in most but not all cases of AITL, the following three subclassifications have been introduced:

AITL with no evidence of clonal lymphoid proliferation
AITL-type dysplasia with inconsistent findings regarding the clonality of the proliferating cells
AITL-type lymphoma with strong evidence of clonality by immunohistochemical tests, rearrangement analysis, and cytogenetic studies

AITL-type dysplasia with an oligoclonal T-cell pattern has frequently been shown to progress into AITL-type lymphoma. Thus, this subclassification may reflect the existence of stages in the development of the disease rather than independent disease entities.

Krenacs et al have suggested that the phenotype of neoplastic cells in AITL appears consistent with the phenotype of activated follicular B-helper T cells.[2] It has become clear that AITL is a clonal T-cell disorder involving deregulation of B-cells and endothelial cells against a background involving a unique malignant microenvironment.

Biopsies of the bone marrow, lymph node, and skin are key in diagnosing AITL (see Workup). Many agents have been used to treat AITL, but none has proved universally or consistently effective (see Treatment and Management).

AITL can occur with other neoplasms. AITL has been reported to occur concurrently with plasma cell leukemia.[3] AITL has also been noted to manifest with a leukemic presentation.[4]

For other discussions on lymphoma, see the overview topic Non-Hodgkin Lymphoma.

Pathophysiology

Evidence exists that angioimmunoblastic T-cell lymphoma (AITL) develops in a serial fashion. The initial reaction may be an unbalanced immune response to an unknown antigen. This stage is followed by an oligoclonal phase that is driven by persistence and ineffective handling of the primary and initial stimulus. Further events, assumed to take place on a molecular level, may then evolve into malignant monoclonal disease.

In AITL, the factors that result in the serial evolution into malignant lymphoma have yet to be defined. Patients frequently pass through a phase of atypical immune reactions, such as an allergic drug reaction or an allergic reaction to an arthropod bite. Latent viral infection may also be involved (see Etiology).

AITL is mainly derived from CD2+ CD3+ CD4+ CD5+ CD7- mature T-helper cells with varying expression and partial loss of detectable CD4. A significant number of non-neoplastic T cells (resting CD4+ T cells and activated small- or medium-sized CD8+ lymphocytes) may coexist with a minor neoplastic T-cell population.

Dunleavy et al noted that overexpression of the chemokine CXCL13 and vascular endothelial growth factor–A in AITL suggests that it may be derived from follicular helper T cells.[5]

Using immunohistochemistry, Grogg et al noted CD10 and CXCL13 staining in bone marrow samples in a subset of patients with AITL.[6] The lymphomatous infiltrate in some bone marrow specimens from these AITL patients contained numerous small or scattered large B cells, and these cells resembled either benign lymphoid aggregates or T-cell–rich large B-cell lymphoma, respectively. Trilineage hematopoietic hyperplasia and plasmacytosis were other changes noted by Grogg et al.

Murakami et al reported that the oncogene c-Maf was expressed in the majority of AITLs studied.[7] c-Maf is also overexpressed in approximately half of multiple myelomas.

Tripodo et al have suggested that mast cells have a role in the proinflammatory microenvironment of AITL.[8] They observed that mast cells, which preferentially occurred in AITL cases, directly synthesized interleukin 6 and correlated with the presence of interleukin 17–producing T cells.

In late 2013, Kashara et al reported on 85 cases of AITL with 219 genes from the United States and Europe. All cases had TET2 mutations. In addition, loss-of-function mutations were noted: 4 in TP53, 3 in ETV6, 2 in CCND3, and 5 in EP300. Gain-of-function mutations were also found: 2 in JAK2, and 4 in STAT3 (n=4).[9]

In a separate study, somatic RHOA mutations that encoded a p.Gly17Val alteration were found in 68% of AITL samples. Interestingly, whenever the mutation p.Gly17Val occurred, the TET2 mutation occurred as well.[10]

Elevated absolute monocyte numbers can predict unfavorable outcomes in AITL.[11]

Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) and their clinicopathological implications were investigated in peripheral T-cell lymphoma (PTCL), including AITL.[12]

Etiology

Data from in situ hybridization and polymerase chain reaction tests suggest that angioimmunoblastic T-cell lymphoma (AITL) may be linked to latent infection with a variety of viruses, such as Epstein-Barr virus (EBV),[13] cytomegalovirus (CMV), and herpesvirus type 6. A deletion mutant of the LMP1 oncogene of EBV is associated with the evolution of angioimmunoblastic lymphadenopathy into B immunoblastic lymphoma.

The body's immune system is also thought to misapprehend some antigens, resulting in the cascade of cytokines and gene expression that underlies AITL. The actual proximate cause is not known. The role of EBV infection in skin lesions is not clear.

Patients with Sjögren syndrome are at increased risk for developing lymphoma. Although most lymphomas in these patients are of the B-cell variety, AITL constitutes the majority of T-cell lymphomas associated with Sjögren syndrome.[14]

Medications linked to the induction of AITL include salazosulfapyridine, azithromycin, and doxycycline.

Epidemiology

The exact incidence of angioimmunoblastic T-cell lymphoma (AITL) is not known. In the United States, approximately 1-2% of non-Hodgkin lymphomas are associated with AITL. In one case series in Korea, 1 of 78 cases of lymphoma was diagnosed as AITL. In a series of 3194 cases of lymphoma in Japan, 2.35% were diagnosed as AITL.

The female-to-male ratio in AITL remains uncertain. In 2000, in a series of 10 patients, Martel et al reported 7 women and 3 men.[15] In 1995, Siegert et al reported a female-to-male ratio of 1:1.4 in a series of 62 patients.[16]

Although AITL has been reported in children, most patients are middle aged or elderly. Siegert et al reported a median patient age of 64 years (range, 21-87 y) in a series of 62 patients.[16]

Prognosis

Overall, angioimmunoblastic T-cell lymphoma (AITL) has a moderately aggressive course, with occasional spontaneous remissions or protracted responses to therapy. The median survival is 24 months. AITL can evolve into high-grade lymphomas of T- or B-cell type, Epstein-Barr virus (EBV)–positive B-cell lymphomas, and chronic lymphatic leukemia (CLL), among other kinds of lymphoma and leukemia. Most patients eventually die of infections due to immunologic compromise.

A univariate analysis by Siegert et al showed that survival was significantly related to the following[16] :

Age
Stage
Rash/pruritus
Edema
Ascites
Number of clinical symptoms
LDH level
Hemoglobin level

Schlegelberger et al found that certain cytogenetic findings were associated with a significantly lower incidence of therapy-induced remissions and a significantly shorter survival duration.[17] These cytogenetic findings included the following:

Aberrant metaphases in unstimulated cultures
Clones with an additional X chromosome
Structural aberrations of the short arm of chromosome 1, preferentially involving 1p31-32
Complex aberrant clones with more than four aberrations

Patient Education

Patients and their families must understand that angioimmunoblastic T-cell lymphoma (AITL) is usually a fatal disease and is accompanied by many potentially serious infections.

For patient education information, see the Cancer Center, as well as Lymphoma and Skin Cancer.

Presentation

History

Angioimmunoblastic T-cell lymphoma (AITL) usually starts in a nonspecific fashion. Clinical manifestations are typical of lymphoma and may include the following:

Maculopapular rashes (these can resemble a viral rash)
Seropositive polyarthritis
Fever
Pruritus
Lymphadenopathy
Night sweats
Weight loss
Edema

As the disease progresses, patients may experience bone pain, ascites, and hepatosplenomegaly. Initially, AITL has a waxing and waning course; however, as it progresses, symptoms persist.

Patients can present with unusual infections. For example, Mönkemüller and Bronze reported a case of immunoblastic lymphadenopathy that presented as an acute abdomen and mixed bacteremia with Eikenella corrodens and group C Streptococcus infection.[18] Some patients have had disseminated infections with herpesvirus type 6 and other viral infections.

Incongruous clinical symptoms raise the possibility of AITL. For example, one reported case of AITL manifested as sick sinus syndrome, and others have had the appearance of collagen vascular diseases. Some patients have a history of collagen-vascular diseases, such as rheumatoid arthritis and dermatomyositis.

AITL can mimic tuberculosis. Singh et al reported a case of AITL with pulmonary involvement that was initially mistaken for tuberculosis based on fine-needle aspiration cytology and was treated with antituberculous therapy for 3 months.[19] The case was subsequently diagnosed as AITL based on lymph node biopsy results.

Hosoki et al described AITL developing with lymphocytic pleural effusion.[20]

Rare cases of AITL associated with proliferative glomerulonephritis have been reported. De Samblanx et al described a 67-year-old man with a nephrotic syndrome secondary to a proliferative glomerulonephritis, which was coincident with AITL.[21]

Batinac et al reported a case of AITL in an elderly patient who presented with generalized pruritic maculopapular eruption and fever after taking doxycycline.[22] Renner et al described eosinophilic cellulitis (Wells syndrome) in association with angioimmunoblastic lymphadenopathy.[23]

Physical Examination

All organ systems can be affected by AITL. Typical findings at presentation include the following:

Rash (50% of cases)
Pruritus (30%)
Edema (40%)
Pleural effusion (40%)
Arthritis (20%)
Ascites (25%)

Skin manifestations are the presenting sign of AITL in 40-50% of patients. Cutaneous involvement by AITL exhibits a highly variable presentation, typically with mixed features of an erythematous eruption with or without papules. The most commonly described lesions are a nonspecific morbilliform eruption mimicking a viral exanthem or drug eruption. Approximately 50% of patients with AITL-associated rash report pruritus. Other skin manifestations reported include nodules, annular lesions, and erythroderma. Vasculitis has been reported in AITL, including leukocytoclastic vasculitis, cutaneous medium-vessel vasculitis, and paraneoplastic vasculitis.[24]

There also are reports of patients with AITL with chronic urticarial eruptions.[24]

Skin laxity has been reported as a presenting sign of AITL.[25] Linear IgA dermatosis associated with cutaneous involvement of AITL has been reported. The patient presented with lesions that resembled toxic epidermal necrolysis, and immunofluorescence study revealed heavy IgA linear deposition in the dermoepidermal junction.[26]

Ferran et al suggested that the "deck-chair sign" (ie, rash with sparing of skin creases) is specific for cutaneous involvement by AITL.[27] AITL with scleromyxedemalike lesions and serum monoclonal protein has been reported,[28] as have subcorneal pustules and deep dermal-hypodermal nodules[29] and toxic epidermal necrolysis.[30]

Other possible findings include systemic lymphadenopathy, lacrimal and salivary gland involvement, and hepatosplenomegaly. Renal findings include renal amyloidosis, proliferative glomerulonephritis, and acute interstitial nephritis. Miura et al reported acute renal failure resulting from immunoglobulin M–lambda glomerular thrombi and membranoproliferative glomerulonephritis–like lesions in a patient with AITL.[31]

Pulmonary findings are varied and include hypoxemia. Some patients have interstitial pneumonia or bronchopneumonia. Patients with bronchopneumonia can have opportunistic infections, such as Pneumocystis jiroveci pneumonia; a case of cytomegalovirus infection has also been reported. Jarrett et al reported a case of shortness of breath and peripheral edema.[32]

Neurologic, rheumatologic, and related findings include retrobulbar neuritis, neuropathy, polyneuropathy, arthritis, papilledema, myelofibrosis, and inflammatory myopathy.

Goenka et al described a case of angioimmunoblastic lymphadenopathy with multiple polyps of the gastrointestinal tract. The patient presented with fever, abdominal mass, ascites, diarrhea, generalized lymphadenopathy, anemia, and marked peripheral eosinophilia.[33]

Complications

Angioimmunoblastic T-cell lymphoma (AITL) is frequently associated with immunological abnormalities, including autoimmune cytopenias, hypergammaglobulinemia, and the presence of various autoantibodies. A few reports on AITL have also described the development of myelofibrosis.[34]

Pure red cell aplasia due to AITL has also been reported.[35]

DDx

Diagnostic Considerations

Angioimmunoblastic T-cell lymphoma (AITL) must be distinguished from reactive processes that mimic it.[36] AITL is usually diagnosed at advanced stages because its symptoms are nonspecific; thus, in older people, so-called B symptoms (ie, fever, weight loss, lymphadenopathy) should prompt investigation for AITL, leukemia, and lymphoma.

Reactive processes can mimic AITL; moreover, infections can occur with AITL, and AITL can evolve into high-grade lymphoma. These situations should be considered when assessing and treating AITL.

Other problems to be considered in patients with possible AITL include the following:

Multicentric giant lymph node hyperplasia
Acute viral lymphadenitis
Hypersensitivity syndrome (eg, dapsone) ^[37]
Lymphoma
Leukemia
Viral exanthema
Crohn disease ^[38]
Atypical linear immunoglobulin A dermatosis ^[39]

Workup

Laboratory Studies

Almost any laboratory value can be abnormal in angioimmunoblastic T-cell lymphoma (AITL). As is true with its clinical symptoms, the presence of incongruous laboratory values, especially pancytopenia, should prompt a consideration of AITL as a diagnosis.

Patients with AITL may exhibit laboratory findings characteristic of autoimmune disease, such as the following:

Circulating immune complexes
Anti–smooth muscle antibodies
Rheumatoid factor
Autoimmune hemolysis
Cold agglutinins
Paraproteinemia
Anticardiolipin antibodies
Rheumatoid factor (less common)
Cryoglobulins (less common)

Other blood chemistry values that can be abnormal include the following:

Erythrocyte sedimentation rate (almost all cases)
Lactate dehydrogenase (LDH) level (commonly increased)
Polyclonal gamma globulins (common)

Anemia with hemoglobin with values below 10 g/dL can be present, and a direct Coombs test can be positive. Often, thrombocytopenia with platelet counts below 100 × 109/L is present. Platelet-associated immunoglobulin G can be present. In many patients, whole complement activity (CH50) is reduced. Pancytopenia can also be present. These changes are related to compromised bone marrow function.

In some cases, trisomies 3, 5, and X in AITL can be detected with fluorescence in situ hybridization (FISH). Cells with +5, +15, +19, +21, and +22 trisomies have been seen as well.

AITL shows a high proportion of tumor necrosis factor alpha–positive T-lymphocytes. In addition, the percentages of interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, and interferon-gamma–positive T-lymphocyte counts are relatively higher than in other diseases. These data underlie the state of multiple hypercytokinemia typically observed in AITL.

Flow cytometry has potential utility for the diagnosis of AITL.[40, 41, 42] Chen et al reported that multiparameter flow cytometry identified a distinct population of immunophenotypically aberrant T cells in 15 of 16 cases.[40] Yuan et al suggested that finding coexpression of CD10 on flow cytometry can help discriminate AITL from other peripheral T-cell lymphomas (PTCLs).[42]

Tumor cells in AITL express T-cell–associated antigens and are usually CD4 positive. The clonality of cells can be detected, with T-cell clonality eventually detected in 75% of cases. After treatment, residual disease can be detected by polymerase chain reaction (PCR) by analyzing the rearrangement of TCR genes. Polymerase chain reaction amplification and sequencing of immunoglobulin H (IgH) genes is advisable because a gene rearrangement is detected in 10% of cases.

Yamane et al reported AITL with polyclonal proliferation of plasma cells in peripheral blood and marrow.[43] Cho et al found that 70% of cases of AITL involve bone marrow and that CD5, bcl-6, and CD10 were useful markers of bone marrow infiltration.[44]

Imaging Studies

Radiographs and CT scans can demonstrate lymphadenopathy. They may also demonstrate pulmonary abnormalities, such as pleural effusions and multiple opacities, predominantly basal, of variable size. Radiographic findings include bilateral mediastinal and hilar lymphadenopathy, pleural effusion, interstitial shadow, alveolar shadow, and atelectasis. Diffuse CT contrast enhancement of cervical lymph nodes can aid in diagnosing angioimmunoblastic lymphadenopathy.

Magnetic resonance imaging of bone marrow can demonstrate angioimmunoblastic lymphadenopathy. MRI scans show lymphadenopathy, but this finding is not diagnostic.

Gallium scans and radiographic appearances may assist in diagnosing AITL, but lymph node biopsy is necessary to distinguish AITL from lymphoma.

Biopsy

Biopsies of the bone marrow, lymph node, and skin are key in diagnosing AITL. AITL is diagnosed by a positive biopsy result obtained from an affected lymph node, although sometimes, biopsy results are only suggestive of AITL, not diagnostic. In patients with ascites (25% of cases), paracentesis with cytologic examination of ascitic fluid is indicated.

Histologic Findings

Skin biopsy samples in AITL demonstrate a perivascular dermal infiltrate with eosinophils, histiocytes, plasma cells, and lymphoid cells. The infiltrate can be patchy. The number of blood vessels can be increased. The endothelial cells, which are often cuboidal, are prominent.

In some cases, skin histologic analysis shows extensive perivascular and periadnexal mixed lymphoid infiltrates, including centroblasts and immunoblasts, with a high proliferative index and with focal erythrocyte extravasation.

In skin lesions, T-cell and B-cell blasts predominate, together with endothelial cell proliferation. T-cell receptor gene rearrangement analysis reveals a monoclonality T cell; however, B-cell proliferations are usually polyclonal.

Histologic examination of the lymph nodes can show nearly complete effacement of the follicular architecture, a mixed lymphoid infiltrate, and numerous high endothelial venules in an expanded T-cell zone. In some cases, the lymph nodes show diffuse obliteration of their architecture by lymphoid infiltrates consisting of lymphocytes, immunoblasts, plasma cells, and histiocytes, together with numerous high endothelial venules surrounded by an expanded network of follicular dendritic cells.

Immunohistochemical analysis can demonstrate preservation of at least some follicular structures.

Attygalle et al reported that clear cells and Epstein-Barr virus (EBV) infection (when present) are useful distinguishing features and that CD10 is a sensitive and specific marker of AITL.[45] Hyperplastic follicles are present in a significant minority of AITL patients.

Sakai et al described an AITL patient initially presenting with replacement of bone marrow with polymorphic cellular infiltrates containing aggregates of CD10-positive T cells, along with peripheral plasmacytosis.[46] Karube et al reported on 11 cases of adult T-cell lymphoma/leukemia in which morphologic features were suggestive of AITL, but the immunohistochemical features of the disease—CD10 and CXCL13 expression in lymphoma cells and proliferation of CD21-positive follicular dendritic cells—were not detected.[47]

Dorfman et al reported that programmed death–1 (PD-1), a member of the CD28 costimulatory receptor family, is expressed by germinal center-associated T cells in reactive lymphoid tissue. These researchers suggest PD-1 as a useful marker for AITL.[48]

Bone marrow infiltration by AITL demonstrates variable patterns that correlate with prognosis. PD-1 and BCL6 can be used to identify lymphoma infiltrates.[49]

Staging

The standard staging system used for angioimmunoblastic T-cell lymphoma (AITL) is the Ann Arbor system which was developed for Hodgkin disease but is also used in non-Hodgkin lymphoma. Unfortunately, the Ann Arbor system does not provide a completely reliable match for prognosis in patients with AITL, but it is the only system available.

The Ann Arbor staging system uses both the number of sites of involvement and the presence of disease above or below the diaphragm. It defines the following 4 stages of disease:

Stage I - Involvement of a single lymph node region (I) or a single extranodal site (IE)
Stage II - Involvement of 2 or more lymph node regions on the same side of the diaphragm (II) or localized involvement of an extralymphatic site (IIE)
Stage III - Involvement of lymph node regions on both sides of the diaphragm (III) and localized involvement of an extralymphatic site (IIIE) or spleen (IIIs) or both (IIIEs)
Stage IV - Diffuse or disseminated involvement of 1 or more extralymphatic organs with or without associated lymph node involvement; localized involvement of liver or bone marrow is also considered stage IV

Patients are divided into 2 subsets according to the absence (subset A) or presence (B) of systemic symptoms. Fever of no evident cause, night sweats, and weight loss of more than 10% of the patient's body weight are considered systemic symptoms. Even though itching is frequently present, it should not be considered a systemic symptom.

Bulky disease (eg, a lesion of 10 cm or more in the longest diameter) is designated by appending "X" to the stage designation. Extranodal involvement is identified by the following modifiers:

O – Bone
L – Lung
D – Skin

Treatment

Medical Care

Many agents have been used to treat angioimmunoblastic T-cell lymphoma (AITL), but none has proved universally or consistently effective. The dosing regimens of these treatments have not been definitively set.

Corticosteroids have long been first-line agents for AITL.[50] Prednisone has been used alone or in combination with cyclophosphamide, vincristine, or both. The combination of cyclophosphamide, daunorubicin, Oncovin (vincristine), and prednisone (CHOP) has been used before or after prednisone and with or without interferon-alfa as consolidation. In retrospective analyses, CHOP and CHOP-based regimens have produced complete remission rates of about 60%.[51, 52]

In 2018, the US Food and Drug Administration approved brentuximab vedotin for treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCLs), including AITL and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP). Approval as frontline therapy was based on the ECHELON-2 phase 3 clinical trial (n = 452). Brentuximab plus CHP was superior to CHOP for progression-free survival (P = .011). Overall survival was also improved compared with CHOP (P = .024).[53]

Two thirds of patients treated with low doses of recombinant interferon alfa-2a (used as a single agent) achieved an objective remission, while, in the remaining one third of patients, no change or progressive disease was observed. The median remission duration was 3.5 months. Thus, interferon seems a promising agent in the treatment of AITL, but its role must be further defined.

Other therapeutic approaches that have been tried include the following:

Radiation therapy
Cyclosporine, 2-chlorodeoxyadenosine, and cyclophosphamide
Cyclophosphamide, Oncovin (vincristine), prednisone, bleomycin, Adriamycin (doxorubicin), and Matulane (procarbazine) (COP-BLAM)
Ifosfamide, mesna uroprotection, methotrexate, and etoposide (IMVP-16)
Rituximab ^[54]

Methotrexate has not been found to be effective.

High-dose chemotherapy followed by autologous bone marrow transplantation represents a promising new treatment modality for patients with advanced lymphoma and may conceivably be useful in AITL. Rodríguez et al described prolonged survival for patients with AITL after high-dose chemotherapy and autologous stem cell transplantation.[55] Shinohara et al reported durable remission after the administration of rituximab for Epstein-Barr virus (EBV)–negative, diffuse large B-cell lymphoma that developed after autologous peripheral blood stem cell transplantation for AITL.[56]

Dunleavy et al have suggested that novel therapeutic strategies that include immunomodulation with agents such as cyclosporine and angiogenesis inhibition with drugs such as bevacizumab may prove helpful.[5] There are reports of sustained remission from AITL induced by alemtuzumab.[57, 58]

Bendamustine has shown promise as a treatment agent for patients with angioimmunoblastic lymphadenopathy in a phase 2 trial, in particular in this study of 60 patients, 27 (45%) of whom were refractory to previous treatments.[59]

Korean researchers reported on a case of cervical lymphadenopathy mimicking AITL that was actually dapsone-induced hypersensitivity syndrome. It promptly responded to steroid therapy.[37]

A report in 2013 from the Netherlands noted a response to lenalidomide durable out to 2 years in a patient refractory to 2 other lines of chemotherapy treatment.[60]

Surgical Care

In a few cases, the removal of the spleen has improved the symptoms of angioimmunoblastic T-cell lymphoma (AITL) or induced remission. A 5-month-old girl with AITL was treated with interferon-alfa, cyclosporin A, deoxyspagarine, and azathioprine, alternating regimens of low-dose 6-mercaptopurine, cyclophosphamide, and methotrexate, and results were inconsistent. At age 58 months, a splenectomy was performed, which induced a prolonged complete remission of the AITL, without any medication.

Nakashima et al reported successful coil embolization of a ruptured hepatic aneurysm in a patient with polyarteritis nodosa accompanied by AITL.[61]

Consultations

Management of angioimmunoblastic T-cell lymphoma (AITL) requires consultations with all specialists who can deal with its myriad specific manifestations. An oncologist/hematologist should supervise the care of these patients. Because most patients die of infectious complications, an infectious disease specialist should also be involved.

Long-Term Monitoring

Patients must be monitored for infections and must be educated about the importance of seeking medical care if they develop a fever or other constitutional symptoms. In most patients, angioimmunoblastic T-cell lymphoma (AITL) eventually progresses to immunocompromise, and the assessment and treatment of infection becomes a critical aspect of care.

Medication

Medication Summary

Antineoplastics, Anti-CD30 Monoclonal Antibodies

Class Summary

Antibody conjugate binds to cells expressing the CD30 antigen and forms a complex that is internalized within the cell and monomethyl auristatin E (MMAE) is released; MMAE induces cell cycle (G2/M phase) arrest by binding to tubules and disrupting the cellular microtubule network.

Brentuximab vedotin (Adcetris)

Brentuximab vedotin is a CD30-directed antibody-drug conjugate (ADC) consisting of chimeric IgG1 antibody cAC10, specific for human CD30 and the microtubule disrupting agent, MMAE, or vedotin. It is indicated for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing PTCLs, including AITL and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1974 Jun 1. 1(7866):1070-3. [QxMD MEDLINE Link].
Krenacs L, Schaerli P, Kis G, Bagdi E. Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood. 2006 Aug 1. 108(3):1110-1. [QxMD MEDLINE Link].
Jang MA, Lee ST, Kim HJ, Kim S, Kim SH. Simultaneous occurrence of angioimmunoblastic T-cell lymphoma and plasma cell leukemia. Ann Lab Med. 2015 Jan. 35(1):149-51. [QxMD MEDLINE Link].
Lin KW, Lee YS, Phipps C. Leukaemic presentation of angioimmunoblastic T-cell lymphoma. Br J Haematol. 2014 Sep. 166(6):808. [QxMD MEDLINE Link].
Dunleavy K, Wilson WH, Jaffe ES. Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Curr Opin Hematol. 2007 Jul. 14(4):348-53. [QxMD MEDLINE Link].
Grogg KL, Morice WG, Macon WR. Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol. 2007 Jun. 137(5):416-22. [QxMD MEDLINE Link].
Murakami YI, Yatabe Y, Sakaguchi T, Sasaki E, Yamashita Y, Morito N, et al. c-Maf expression in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2007 Nov. 31(11):1695-702. [QxMD MEDLINE Link].
Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S, et al. Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010 Aug. 177(2):792-802. [QxMD MEDLINE Link]. [Full Text].
Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N. A targeted mutational landscape of angioimmunoblastic T cell lymphoma. Blood. 2013 Dec 17. [QxMD MEDLINE Link].
Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014 Jan 12. [QxMD MEDLINE Link].
Yang YQ, Liang JH, Wu JZ, Wang L, Qu XY, Cao L, et al. Elevated absolute monocyte count predicts unfavorable outcomes in patients with angioimmunoblastic T-cell lymphoma. Leuk Res. 2015 Dec 24. [QxMD MEDLINE Link].
Kim S, Kwon D, Koh J, Nam SJ, Kim YA, Kim TM, et al. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified. Virchows Arch. 2020 Mar 13. [QxMD MEDLINE Link].
Hawley RC, Cankovic M, Zarbo RJ. Angioimmunoblastic T-cell lymphoma with supervening Epstein-Barr virus-associated large B-cell lymphoma. Arch Pathol Lab Med. 2006 Nov. 130(11):1707-11. [QxMD MEDLINE Link].
Saito M, Fukuda T, Shiohara T, Homori M. Angioimmunoblastic T-cell lymphoma: a relatively common type of T-cell lymphoma in Sjögren's syndrome. Clin Exp Rheumatol. 2005 Nov-Dec. 23(6):888-90. [QxMD MEDLINE Link].
Martel P, Laroche L, Courville P, Larroche C, Wechsler J, Lenormand B, et al. Cutaneous involvement in patients with angioimmunoblastic lymphadenopathy with dysproteinemia: a clinical, immunohistological, and molecular analysis. Arch Dermatol. 2000 Jul. 136(7):881-6. [QxMD MEDLINE Link].
Siegert W, Nerl C, Agthe A, Engelhard M, Brittinger G, Tiemann M, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol. 1995 Sep. 6(7):659-64. [QxMD MEDLINE Link].
Schlegelberger B, Zwingers T, Hohenadel K, Henne-Bruns D, Schmitz N, Haferlach T, et al. Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type. J Clin Oncol. 1996 Feb. 14(2):593-9. [QxMD MEDLINE Link].
Mönkemüller KE, Bronze MS. Immunoblastic lymphadenopathy presenting as an acute abdomen and mixed bacteremia with Eikenella corrodens and group C streptococci. Am J Gastroenterol. 1998 Apr. 93(4):652-3. [QxMD MEDLINE Link].
Singh MK, Solanki RN, Shah NJ, Tanna D, Patel DR, Desai IM. Angioimmunoblastic lymphadenopathy with dysproteinemia: thoracic involvement. Indian J Chest Dis Allied Sci. 2004 Apr-Jun. 46(2):125-8. [QxMD MEDLINE Link].
Hosoki K, Okada S, Ichinohasama R, Yamaguchi M, Uchiyama B, Maeyama T. Angioimmunoblastic T-cell lymphoma developed with lymphocytic pleural effusion. Intern Med. 2007. 46(11):739-42. [QxMD MEDLINE Link].
De Samblanx H, Verhoef G, Zachée P, Vandenberghe P. A male with angioimmunoblastic T-cell lymphoma and proliferative glomerulonephritis. Ann Hematol. 2004 Jul. 83(7):455-9. [QxMD MEDLINE Link].
Batinac T, Zamolo G, Jonjic N, Gruber F, Nacinovic A, Seili-Bekafigo I, et al. Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration. Tumori. 2003 Jan-Feb. 89(1):91-5. [QxMD MEDLINE Link].
Renner R, Kauer F, Treudler R, Niederwieser D, Simon JC. Eosinophilic cellulitis (Wells' syndrome) in association with angioimmunoblastic lymphadenopathy. Acta Derm Venereol. 2007. 87(6):525-8. [QxMD MEDLINE Link].
Hoskins S, Moriarty N, White K, Kalus A, Shustov A, Shinohara MM. Cutaneous manifestations of angioimmunoblastic T-cell lymphoma. Dermatol Online J. 2019 Jul 15. 25 (7):[QxMD MEDLINE Link].
Maher NG, Chiang YZ, Badoux X, Vonthethoff LW, Murrell DF. Saggy skin as a presenting sign of angioimmunoblastic T-cell lymphoma. Clin Exp Dermatol. 2015 Dec 1. [QxMD MEDLINE Link].
Colmant C, Camboni A, Dekeuleneer V, Marot L, Dachelet C, Baeck M. Linear IgA dermatosis in association with angioimmunoblastic T-cell lymphoma infiltrating the skin: A case report with literature review. J Cutan Pathol. 2020 Mar. 47 (3):251-256. [QxMD MEDLINE Link].
Ferran M, Gallardo F, Baena V, Ferrer A, Florensa L, Pujol RM. The 'deck chair sign' in specific cutaneous involvement by angioimmunoblastic T cell lymphoma. Dermatology. 2006. 213(1):50-2. [QxMD MEDLINE Link].
Rahmani R, Brenner S, Krakowski A, Lipitz R, Ilie B, Behar AJ. Angioimmunoblastic lymphadenopathy with scleromyxedema-like lesions and serum monoclonal protein. Isr J Med Sci. 1983 Mar. 19(3):235-9. [QxMD MEDLINE Link].
Sellier S, Levesque H, Courville P, Joly P. [Cyclophosphamide-induced neutrophilic disease in a patient with angioimmunoblastic lymphadenopathy and myelodysplastic syndrome]. Ann Dermatol Venereol. 2006 May. 133(5 Pt 1):459-62. [QxMD MEDLINE Link].
Jones B, Vun Y, Sabah M, Egan CA. Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma. Australas J Dermatol. 2005 Aug. 46(3):187-91. [QxMD MEDLINE Link].
Miura N, Suzuki K, Yoshino M, Kitagawa W, Yamada H, Ohtani H, et al. Acute renal failure due to IgM-lambda glomerular thrombi and MPGN-like lesions in a patient with angioimmunoblastic T-Cell lymphoma. Am J Kidney Dis. 2006 Jul. 48(1):e3-9. [QxMD MEDLINE Link].
Jarrett R, Walk N, Castellano-Sanchez AA, Kreisel FH. A 68-year-old man with shortness of breath and peripheral edema. Angioimmunoblastic T-cell lymphoma. Arch Pathol Lab Med. 2006 Feb. 130(2):219-22. [QxMD MEDLINE Link].
Goenka MK, Vaiphei K, Nagi B, Sriram PV, Joshi K, Kochhar R. Angioimmunoblastic lymphadenopathy: an etiology for gastrointestinal lymphomatous polyposis. Am J Gastroenterol. 1996 Jun. 91(6):1236-8. [QxMD MEDLINE Link].
Matsuura M, Koshiishi M, Suzuki J, Suzuki M, Kawashima I, Nakajima K, et al. [Angioimmunoblastic T-cell lymphoma complicated with various autoimmune abnormalities and myelofibrosis]. Rinsho Ketsueki. 2020. 61 (2):110-115. [QxMD MEDLINE Link].
Vitorino M, Nunes F, Costa M, Porteiro B, Borges AR, Machado J. Case Report: Pure Red Cell Aplasia due to Angioimmunoblastic T-Cell Lymphoma. Case Rep Oncol. 2020 Jan-Apr. 13 (1):76-78. [QxMD MEDLINE Link].
Brown JR, Skarin AT. Clinical mimics of lymphoma. Oncologist. 2004. 9(4):406-16. [QxMD MEDLINE Link].
Rim MY, Hong J, Yo I, et al. Cervical lymphadenopathy mimicking angioimmunoblastic T-cell lymphoma after dapsone-induced hypersensitivity syndrome. Korean J Pathol. 2012 Dec. 46(6):606-10. [QxMD MEDLINE Link]. [Full Text].
Kang HY, Hwang JH, Park YS, Bang SM, Lee JS, Chung JH, et al. Angioimmunoblastic T-cell lymphoma mimicking Crohn's disease. Dig Dis Sci. 2007 Oct. 52(10):2743-7. [QxMD MEDLINE Link].
Nassar D, Gabillot-Carré M, Ortonne N, Belhadj K, Allanore L, Roujeau JC, et al. Atypical linear IgA dermatosis revealing angioimmunoblastic T-cell lymphoma. Arch Dermatol. 2009 Mar. 145(3):342-3. [QxMD MEDLINE Link].
Chen W, Kesler MV, Karandikar NJ, McKenna RW, Kroft SH. Flow cytometric features of angioimmunoblastic T-cell lymphoma. Cytometry B Clin Cytom. 2006 May. 70(3):142-8. [QxMD MEDLINE Link].
Todd T, Erber W. Diagnosis of leukaemic phase of angioimmunoblastic T-cell lymphoma from the peripheral blood. Br J Haematol. 2006 Jul. 134(2):124. [QxMD MEDLINE Link].
Yuan CM, Vergilio JA, Zhao XF, Smith TK, Harris NL, Bagg A. CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. Hum Pathol. 2005 Jul. 36(7):784-91. [QxMD MEDLINE Link].
Yamane A, Awaya N, Shimizu T, Ikeda Y, Okamoto S. Angioimmunoblastic T-cell lymphoma with polyclonal proliferation of plasma cells in peripheral blood and marrow. Acta Haematol. 2007. 117(2):74-7. [QxMD MEDLINE Link].
Cho YU, Chi HS, Park CJ, Jang S, Seo EJ, Huh J. Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement. Am J Clin Pathol. 2009 May. 131(5):640-6. [QxMD MEDLINE Link].
Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A. Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology. 2007 Mar. 50(4):498-508. [QxMD MEDLINE Link].
Sakai H, Tanaka H, Katsurada T, Yoshida Y, Okamoto E, Ohno H. Angioimmunoblastic T-cell lymphoma initially presenting with replacement of bone marrow and peripheral plasmacytosis. Intern Med. 2007. 46(7):419-24. [QxMD MEDLINE Link].
Karube K, Suzumiya J, Okamoto M, Takeshita M, Maeda K, Sakaguchi M, et al. Adult T-cell lymphoma/leukemia with angioimmunoblastic T-cell lymphomalike features: Report of 11 cases. Am J Surg Pathol. 2007 Feb. 31(2):216-23. [QxMD MEDLINE Link].
Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006 Jul. 30(7):802-10. [QxMD MEDLINE Link].
Gerlach MM, Juskevicius D, Vela V, Dirnhofer S, Tzankov A. Bone Marrow Infiltration of Angioimmunoblastic T-Cell Lymphoma. Arch Pathol Lab Med. 2019 Sep 26. [QxMD MEDLINE Link].
Matsumiya H, Arai A, Nagai A. [A case of angioimmunoblastic T-cell lymphoma with interstitial shadow which disappeared after injection of hydrocortisone]. Nihon Kokyuki Gakkai Zasshi. 2006 Jul. 44(7):537-40. [QxMD MEDLINE Link].
Alizadeh AA, Advani RH. Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clin Adv Hematol Oncol. 2008 Dec. 6(12):899-909. [QxMD MEDLINE Link].
Pautier P, Devidas A, Delmer A, Dombret H, Sutton L, Zini JM, et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma. 1999 Feb. 32(5-6):545-52. [QxMD MEDLINE Link].
Horwitz SM, O’Connor OA, Pro B, Illidge TM, Fanale MA, Advani RH, et al. The ECHELON-2 Trial: Results of a randomized, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (oral presentation 997). Presented at the American Society of Hematology (ASH) 2018 Annual Meeting. San Diego, CA. December 3, 2018. [Full Text].
Kasahara H, Kakimoto T, Saito H, Akuta K, Yamamoto K, Ujiie H, et al. Successful treatment with rituximab for angioimmunoblastic T-cell lymphoma. Leuk Res Rep. 2013 May. 2(1):36-8. [QxMD MEDLINE Link].
Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol. 2007 Apr. 78(4):290-6. [QxMD MEDLINE Link].
Shinohara A, Asai T, Izutsu K, Ota Y, Takeuchi K, Hangaishi A, et al. Durable remission after the administration of rituximab for EBV-negative, diffuse large B-cell lymphoma following autologous peripheral blood stem cell transplantation for angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2007 Feb. 48(2):418-20. [QxMD MEDLINE Link].
Halene S, Zieske A, Berliner N. Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab. Nat Clin Pract Oncol. 2006 Mar. 3(3):165-8; quiz 169. [QxMD MEDLINE Link].
Amengual JE, Raphael BG. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2010 Jul. 51(7):1347-50. [QxMD MEDLINE Link].
Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013 Jan 1. 31(1):104-10. [QxMD MEDLINE Link].
Beckers MM, Huls G. Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide. Eur J Haematol. 2013 Feb. 90(2):162-3. [QxMD MEDLINE Link].
Nakashima M, Suzuki K, Okada M, Takada K, Kobayashi H, Hama Y. Successful coil embolization of a ruptured hepatic aneurysm in a patient with polyarteritis nodosa accompanied by angioimmunoblastic T cell lymphoma. Clin Rheumatol. 2007 Aug. 26(8):1362-4. [QxMD MEDLINE Link].